Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

FHTX Foghorn Therapeutics

Watchlist
13.980
+0.380+2.79%
Close 07/01 16:00 ET
13.98000.00%
Post Mkt Price 07/01 16:04 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
14.075
Open
13.630
Turnover
643.81K
Low
13.565
Pre Close
13.600
Volume
46.28K
Market Cap
579.72M
P/E(TTM)
Loss
52wk High
24.340
Shares
41.47M
P/E(Static)
Loss
52wk Low
8.010
Float Cap
278.55M
Bid/Ask %
0.00%
Historical High
28.265
Shs Float
19.93M
Volume Ratio
0.30
Historical Low
8.010
Dividend TTM
--
Div Yield TTM
--
P/B
8.01
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.23%
Amplitude
3.75%
Avg Price
13.911
Lot Size
1
Float Cap
278.55M
Bid/Ask %
0.00%
Historical High
28.265
Shs Float
19.93M
Volume Ratio
0.30
Historical Low
8.010
Dividend TTM
--
P/B
8.01
Dividend LFY
--
Turnover Ratio
0.23%
Amplitude
3.75%
Avg Price
13.911
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
CEO: Gottschalk, Adrian H. B.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top